Drug giants eye China for deals, despite growing Sino-US tensions

Quick Summary:

Foreign acquisitions in 2024 accounted for US$720 million in value, down 52 per cent year on year.

The majority of buyers of Chinese healthcare companies have been domestic in the past two decades, London Stock Exchange Group data showed.

Sanofi product planning manager Wei Wei told Reuters that buying biotechnology companies in China was a goal for the French drugmaker and had been discussed in meetings.

---

More Pictures

---

Read Quick SummarySave Time

or

Article Details

Category: EconomyBusiness

Markets: SingaporeChinaHong KongSouth Africa

Topics: Chinese Therapy 2024 Pharmaceutical Company Deals Billion Companies China Been Major

Source Website Secure: Yes (HTTPS)

News Sentiment: Neutral

Fact Checked: Legitimate

Article Type: News Report

Published On: 2024-07-23 @ 10:50:00 (3 hours ago)

News Timezone: GMT +8:00

News Source URL: straitstimes.com

Language: English

Article Length: 652 words

Reading Time: 4 minutes read

Sentences: 24 lines

Sentence Length: 28 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © The Straits Times

News ID: 21744178

View Article Analysis

About The Straits Times

Main Topics: EconomyBusiness

Official Website: straitstimes.com

Update Frequency: 12 posts per day

Year Established: 1845

Headquarters: Singapore

News Last Updated: 4 hours ago

Coverage Areas: Singapore

Ownership: Independent Company

Publication Timezone: GMT +8:00

Content Availability: Local / Regional

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #25

Publisher Details

Frequently Asked Questions